and 0.3% NaCI was started at a rate of 0.1-0.2 ml/min. After a small midsection of the lower abdominal wall, the urinary bladder was exposed and a polyethylene tube (PE 190) was inserted into the bladder through the incised wall to make a bladder fistule.
Experimental protocols
Experimental protocols were usually started at 3-4 hr after the operation when urine flow became constant at a rate of more than 0.15 ml/min.
Urine was collected into small measuring syringes every 10 min. Drugs were injected bolusly into the femoral vein in a volume of 0.1 ml. Drugs were injected repeatedly in the same animal after urine volume returned to the control level. The following 4 experimental protocols were conducted:
Protocol 1: A dose-response relationship between changes in urine volume and doses of bolusly injected arginine vasopressin (AVP) was examined to determine the submaximal dose of AVP.
Protocol 2: This protocol was designed to examine whether dopamine modulates the antidiuretic action of AVP. Soon after observing the antidiuretic effect of 80 /eU AVP, various doses of dopamine in combi nation with 80 /tU of AVP were injected. The doses of dopamine were 0.1 1, 1.1 and 1 1 /cg/100 g body weight. These doses were expected to correspond to 10-7, 10-6 and 10-5 moles/liter plasma concentration, respectively, assuming that plasma volume is 7% of body weight.
Protocol 3: This protocol was designed to examine whether the action of dopamine can be blocked by a dopaminergic antagonist, haloperidol.
Bolus injections of AVP, AVP plus dopamine, and AVP plus dopamine plus haloperidol were performed, consecu tively. Doses of AVP, dopamine and haloperidol were 80 /€U, 1.1 /cg/100 g body weight, and 2.3 /cg/100 g body weight, respectively.
Protocol 4: In order to confirm that dopamine or haloperidol has no effect on basal urine flow, effect of single adminis tration of 0.1, 1 .1 and 11 gig/100 g body weight of dopamine or 2.3 gig/100' g body weight of haloperidol was observed.
Statistical analysis
The urine flow rate in 10 min after adminis tration of agents (A) was divided by that in the 10 min before administration of agents (B). The ratios of (A-B)/B were used as indices of the effect of the agent(s) in question. The data were expressed as means +S .E., and differences between the data of two groups were evaluated by Student's t test for paired samples. The reduction rate of urine flow during the first 10 min were taken as an index of the response to vasopressin. Doses of vasopressin used were 20, 40, 80 and 160 itU/rat. As summarized in Table 1 , the index was dose-dependent from 20 to 80 /tU/rat, and the maximum effect of vasopressin was observed between 80 and 160 !tU/rat. Based on this observation, we assumed that 80 ;tU/rat was the submaximal dose of vasopressin in this preparation.
Modulation by dopamine of the action of AVP (Protocol 2): After confirming that 80 ;tU/rat AVP caused a marked reduction in urine flow, we examined whether dopamine modulates the effect of AVP according to protocol 2. The results are summarized in Table 2 . It is clear that dopamine adminis tration inhibited the action of AVP. This inhibitory effect was much more at 1.1 /cg/ 100 g body weight than 0.1 pg/100 g body weight of dopamine, but no further increase in inhibitory effect was observed at 11 /Ig/ 100 g body weight of dopamine.
Effect of haloperidol (Protocol 3): In order to confirm whether the inhibitory effect of dopamine on AVP action is virtually mediated by a dopaminergic mechanism, we examined the effect of haloperidol on this inhibitory effect of dopamine according to protocol 3. After confirming that in the same animals the action of AVP was inhibited by 1.1 !ig/100 g body weight of dopamine, we tested whether this effect of dopamine can be prevented by 2.3 etg/100 g body weight of haloperidol. The results summarized in Table 3 clearly indicate that haloperidol could in fact prevent the action of dopamine in inhibiting the effect of AVP. Direct effects of dopamine or haloperidol on urine flow rate (Protocol 4): In order to evaluate the observations described above, it is necessary to confirm that dopamine or haloperidol does not cause significant change of urine flow rate in this preparation.
For this purpose, we undertook a series of studies in which effects of 0.1 1, 1.1 and 11 /cg/100 g body weight dopamine or 2.3 iig/ 100 g body weight of haloperidol were observed.
The results are summarized in Table 4 . Although dopamine at a dose of 1 1 itg/100g body weight tended to cause an increase in urine flow, this was not statisti cally significant.
Haloperidol by itself also did not influence urine flow rate in this preparation. However, evidence has been accumulated in support of the view that dopamine acts directly on the renal tubules (6, 7, 13). Bello-Reuss et al. (13) reported that dopamine inhibited sodium transport across the rabbit proximal straight tubule. In addition to direct renal tubular action, dopamine might have inhibitory action on the hydro-osmotic effect of vasopressin, thereby increasing urinary excretion of water (8, 11, 12). and Alonso (8), although the protocols were somewhat different. However, this is con tradictory to the observation of Cadnapa phornchai et al. (14) that in hypophysec tomized dogs, i.v.-infused doparnine did not modulate the effect of 100 mU vasopressin. The reason for this discrepancy is unknown at present. However, it should be noted that the dose of vasopressin in their study ranged from 3 to 5 mU/kg, whereas in our study, it ranged from 0.2 to 0.4 mU/kg, the latter being carefully selected as a submaximal dose. It is possible that the dose of vasopressin in their study was too high to detect an inhibitory effect of dopamine. In the present study, we further confirmed that this inhibitory effect of dopamine on vasopressin action was in fact mediated by dopaminergic receptors, since haloperidol clearly antagonized the action of dopamine.
Therefore, the hydro-osmotic effect of vasopressin is inhibited by a dopaminergic mechanism also in the mam malian kidney as it is in toad bladder (11, 12). 
